Stock DNA
Pharmaceuticals & Biotechnology
CAD 64 Million ()
NA (Loss Making)
NA
0.00%
-0.65
22.24%
-3.00
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Apr 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.75%
0%
-18.75%
6 Months
-18.75%
0%
-18.75%
1 Year
-18.75%
0%
-18.75%
2 Years
-27.78%
0%
-27.78%
3 Years
0%
0%
0.0%
4 Years
-51.85%
0%
-51.85%
5 Years
-75.0%
0%
-75.0%
MedMira, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.52%
EBIT Growth (5y)
-198.08%
EBIT to Interest (avg)
-1.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
-0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.35
EV to EBIT
-24.90
EV to EBITDA
-27.99
EV to Capital Employed
-11.52
EV to Sales
86.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ
Apr'25
Jan'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-0.70
-0.90
22.22%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-1.00
-1.20
16.67%
Operating Profit Margin (Excl OI)
-12,761.40%
-14,400.90%
163.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025
Consolidated Net Profit
QoQ Growth in quarter ended Apr 2025 is 16.67% vs 7.69% in Jan 2025
Annual Results Snapshot (Consolidated) - Jul'24
Jul'24
Jul'23
Change(%)
Net Sales
0.40
0.40
Operating Profit (PBDIT) excl Other Income
-2.10
-1.60
-31.25%
Interest
0.90
0.90
Exceptional Items
0.10
0.20
-50.00%
Consolidate Net Profit
-3.30
-2.70
-22.22%
Operating Profit Margin (Excl OI)
-5,872.60%
-4,223.90%
-164.87%
USD in Million.
Net Sales
YoY Growth in year ended Jul 2024 is 0.00% vs -60.00% in Jul 2023
Consolidated Net Profit
YoY Growth in year ended Jul 2024 is -22.22% vs -50.00% in Jul 2023
About MedMira, Inc. 
MedMira, Inc.
Pharmaceuticals & Biotechnology
MedMira Inc. is a biotechnology company. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company operates through the rapid diagnostic products and services segment. The Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its research focuses on specific areas of the diagnostics market, such as rapid, point-of-care and in vitro sectors. The RVF technology platform includes a three component system: a test cartridge, multi-function buffer and InstantGold Cap. Its technology can be applied in healthcare, research and industrial markets. It offers rapid tests for testing serum, plasma or whole blood specimens. The Company's tests are sold under brands, including Reveal, Multiplo and Miriad. The Company offers rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis.
Company Coordinates 
Company Details
155 Chain Lake Dr.,, Suite 1 , HALIFAX NS : B3S 1B3
Registrar Details






